Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
330 Leser
Artikel bewerten:
(1)

Osteotec and TriMed, Inc., agree distribution partnership for the Osteotec Silicone Finger Implant

NEWBURY, England, June 11, 2024 /PRNewswire/ -- Osteotec, a leading UK manufacturer and distributor of medical devices, is pleased to announce a strategic distribution partnership with TriMed, Inc., a medical device company based in Valencia, California, that develops solutions used in the treatment of orthopaedic injuries.

Osteotec Logo

This collaboration, launched in February, signifies a major advance in Osteotec's mission to extend the reach of its product portfolio across the United States, with a special focus on delivering its flagship product, the Osteotec Silicone Finger Implant.

A one-piece, ?exible silicone elastomer implant, the Osteotec Silicone Finger Implant is designed to improve the function of metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints disabled by osteoarthritis, rheumatoid arthritis or joint trauma and reduce pain in affected joints.

Available in 11 sizes and supplied sterile, the Osteotec Silicone Finger Implant is placed in the proximal and distal intramedullary canals of either MCP or PIP joints during arthroplasty.

"TriMed is not only one of the leading innovators in the field of orthopaedics but shares our commitment to exceptional customer service and providing surgeons with options that improve patient outcomes," said Osteotec Sales and Marketing Director Dean Stockwell.

"Osteotec has successfully distributed the TriMed upper extremity portfolio in the UK for more than a decade, and we are proud to build on this long-term partnership to expand access to our products in the United States.

"We look forward to working with the TriMed team to grow and support sales of the Osteotec Silicone Finger Implant through our shared expertise, ensuring their customers receive the highest quality experience, service and support within the industry."

Designed and manufactured in the UK, the Osteotec Silicone Finger Implant and instrumentation has been in clinical use in the UK for more than 20 years and has been sold in more than a dozen markets across six continents since it was launched in 2004.

The strategic alliance between Osteotec and TriMed, Inc., is expected to make the Osteotec Silicone Finger Implant widely available across the United States for the first time, accelerating growth and contributing to significant sales and revenue increases.

Incorporated in 1997 to advance the treatment of complex periarticular fractures, TriMed's unique methods and inventive technologies have established the company as an industry leader in treating complex musculoskeletal pathologies of the upper and lower extremities.

"We're excited to be offering the Osteotec Silicone Finger Implant to our customers across the United States, and to be bringing another tried and tested product to the market that provides surgeons with more solutions," said TriMed Senior Vice President Jon Mills.

"We think that our team, customers and their patients will benefit from this successful collaboration, and it will also create even more opportunities for growth and ongoing success."

The Osteotec Silicone Finger Implant is available in the United States from TriMed now. For more information, visit trimedortho.com.

Editor's Notes

About Osteotec

Osteotec is a manufacturer and distributor of medical devices headquarter in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 31 years.

Osteotec manufactures the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is a distribution partner of choice for world-leading orthopaedic and spine partners including TriMed, SI-BONE, Enovis and Mathys.

Media Contact:

Ric Sumner
Head of Marketing
ric.sumner@orthocg.com | 020 3011 5574
For more information, visit - www.osteotec.com

About TriMed, Inc.

TriMed, Inc. offers solutions that treat a wide range of musculoskeletal pathologies of the extremities. A market leader that specializes in unique methods of fixation, in addition to its standard methods of fixation, TriMed, Inc. holds numerous patents within the field of orthopaedics. TriMed is headquartered in Valencia, CA with offices in Dublin.

Media Contact:

Jon Mills
Senior Vice President
jonmills@trimedortho.com | (661) 255-7406 x 140
For more information, visit - www.trimedortho.com

Logo - https://mma.prnewswire.com/media/2151731/4753255/Osteotec_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/osteotec-and-trimed-inc-agree-distribution-partnership-for-the-osteotec-silicone-finger-implant-302168391.html

© 2024 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.